Clinical and echocardiographic predictors of early trastuzumab cardiotoxicity in adjuvant treatment of positive human epidermal growth factor receptor type 2 (HER2) breast cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.